Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 4/20 | 0.59 |
| ▸ | XIAP | P98170 | 3/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416762 | 1.00 | NPY1R (0.59) | NPY1RXIAPSCN9AKMT2AL3MBTL1 | |
| SCHEMBL7417336 | 0.91 | NPY1R (0.51) | NPY1RXIAPSCN9AL3MBTL1CCKBR | |
| SCHEMBL7418022 | 0.90 | HDAC1 (0.50) | NPY1RXIAPSCN9APYGL | |
| SCHEMBL7421340 | 0.89 | NPY1R (0.49) | NPY1RXIAPSCN9ACCKBRPYGL | |
| SCHEMBL7421160 | 0.89 | SCN9A (0.48) | NPY1RSCN9ACCKBR | |
| SCHEMBL649566 | 0.88 | NPY1R (0.52) | NPY1RXIAPSCN9AKMT2AL3MBTL1 | |
| SCHEMBL5132457 | 0.88 | NPY1R (0.52) | NPY1RXIAPSCN9AKMT2AL3MBTL1 | |
| SCHEMBL649567 | 0.88 | NPY1R (0.52) | NPY1RXIAPSCN9AKMT2AL3MBTL1 | |
| SCHEMBL5651533 | 0.88 | NPY1R (0.52) | NPY1RXIAPSCN9AKMT2AL3MBTL1 | |
| SCHEMBL7421660 | 0.88 | ACE (0.57) | NPY1RSCN9ACCKBRPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644370-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | disclosed |
| US-7276608-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276608-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276608-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1644370-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007111-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009870-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009870-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | NPY1R 326/4885XIAP 4524/4885SCN9A 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.